Having achieved CE marking, the new OLO system has launched in Europe and non-US countries, while the company is conducting studies necessary for US FDA clearance.

The partners will further develop a test to guide clinical care of patients with Plasmodium vivax malaria who may also have G6PD deficiency.

To detect clinically relevant levels, the magneto-optic system measured magnetic nanocrystals in rabbit blood created by the malaria parasite.

The test will expand the range of diagnostic options available to guide treatment of Plasmodium vivax malaria, which relapses.

Hemex Health is developing a diagnostic test that it said could particularly benefit rural and economically challenged areas of the world. 

Researchers have found that regions limiting the overuse of antimalarial drugs may lead to the overuse of antibiotics instead, among other issues.  

The firm, which raised $7.1 million from its IPO last week, is looking to move into geographies where a need for infectious disease tests are already well established, its CEO said. 

The deal between GE, the Global Good Fund, and Access Bio is to manufacture and distribute malaria diagnostic technologies in low-resource nations.

The commercial future of the test is uncertain, but one of its developers said that work to develop it demonstrates even mature technologies can have new clinical value. 

The test was made about 10 times more sensitive than standard rapid immunoassays by tweaking a number of the firm's proprietary technologies, a company official said.